The global aptamers market size was estimated to be US$ 1.79 billion in 2021 and is expected to grow at a CAGR of 21% between 2023 to 2032.
A short sequence of peptides or oligonucleotides that bind to a particular protein, lipid, or nucleic acid molecule is called an aptamer. Aptamers are primarily utilized for DNA/protein precipitation, suppression, and characterization. Aptamers could be employed as pharmacological leads, detection tools, and active proteomics in combination with small compounds, antibodies, and other aptamers.
Aptamers can be genetically modified to target a variety of targets with increased binding and specificity. Aptamers can also be employed for diagnostics/ treatments instead of antibodies since they are flexible, affordable, and work on similar binding principles.
Aptamers have attracted a lot of attention for prospective therapeutic and diagnostic uses, and they are now more popular than antibodies due to their key benefits, which include lower cost, the ability to not kill nearby cells, higher binding attachment, extended shelf life, and specificity.
The biotechnology sector's expanding capacities for intensive research and development have also contributed to the expansion of the global aptamers market. Aptamers have also become increasingly important for pharmaceutical research and medicinal interventions, and this improved recombinant process of production has created a lucrative potential for market expansion.
Aptamers Market Growth Drivers:
One of the main causes driving the demand for innovative and potent detection assays based on aptamer treatment is the rising prevalence of life-threatening disorders like cancer, neurological, cardiovascular, and acquired immunodeficiency syndrome (AIDS). The economy for aptamers is growing due in part to increased investment in the clinical industry, and an increase in the prevalence of severe and genetic disorders.
An increase in the number of drug development and research for the progress of aptamer-based therapeutic applications, and increased awareness of the advantages of aptamers over monoclonal antibodies will also propel the growth of this market during the forecast period.
Expanding collaborations between research institutions and the pharmaceutical industry, in addition to increased venture capital investment for aptamer investigations, are anticipated to offer market participants a wide range of growth potential. Additionally, the introduction of advanced modification techniques may improve the therapeutic characteristics of aptamers and boost their resistance which will also support the Global aptamers market expansion.
On the contrary hand, a relatively low level of acceptance compared to monoclonal antibodies is anticipated to impede commercial expansion, and a lack of skilled and trained specialists could be a barrier.
The increase in research and development (R&D) expenditures for new diagnostic tools, medications, and their drivers can also be associated with the market expansion for aptamers. Aside from that, the use of aptamers is rapidly expanding worldwide due to their chemical synthesis, which eliminates batch-to-batch variance and requires less time for development.
In addition, various other industries are working with academic institutions and research facilities to launch cutting-edge products and boost their market share. These new methods and techniques are expected to increase demand for a variety of novel medical treatments and also in the food and beverage sector.
Negative Factors:
Strict regulatory guidelines for using aptamers, ethical and social problems with the use of genetic products, and Slow market penetration are anticipated to be a hindrance to the Global Aptamers market progression. The lack of trained and knowledgeable personnel could also restrain the aptamer market's development. Global expansion is also expected to be hampered due to low awareness and adoption in middle and low-income countries. Many aptamer-based products have failed to fulfil all the necessary safety and efficacy standards in clinical research. Such unfavourable properties may also damage the reputation and have a negative effect on the growth of the Aptamers market.
Aptamers Market Regional Segmentation:
United States is dominating the North American aptamers market
The global aptamers market was led by North America mainly because of higher R&D spending and technological developments in this region. Due to encouraging federal programs and an increase in research facilities, the United States is currently dominating the North American market. The European market for aptamers is recognized as the second-largest market in the world. The expansion of the market is actively supported by factors such as the rising prevalence of chronic diseases, the growing number of approvals for advanced clinical technologies, and the rising demand for aptamer-based medicines in Europe.
Combined efforts of the major players in developing countries to penetrate untapped markets are driving the growth of the aptamers market in the Asia-Pacific region. During the projected timeframe, rising R & D expenditures in the pharmaceutical and biotechnology sectors in this region will support the aptamers market expansion. The projection period is likely to see a steady growth rate in the regions of South America, the Middle East, and Africa. Developments in aptamer production are also anticipated to promote the growth of aptamers in South America.
Key Players:
Vivonics Inc., Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC, and Aptamer Sciences Inc. are some of the key players present in the Global Aptamers Market.
Global Aptamers Market Segmentation:
By Type:
By Application:
- Diagnostics
- Therapeutics
- Research and Developments
- Others
By Geography
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
